PE20081750A1 - Derivados de 5-amido-(1h-indol-2-il)-piperazin-1-il-metanona - Google Patents

Derivados de 5-amido-(1h-indol-2-il)-piperazin-1-il-metanona

Info

Publication number
PE20081750A1
PE20081750A1 PE2008000254A PE2008000254A PE20081750A1 PE 20081750 A1 PE20081750 A1 PE 20081750A1 PE 2008000254 A PE2008000254 A PE 2008000254A PE 2008000254 A PE2008000254 A PE 2008000254A PE 20081750 A1 PE20081750 A1 PE 20081750A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
methanone
piperazin
indol
lower alkyl
Prior art date
Application number
PE2008000254A
Other languages
English (en)
Inventor
Matthias Heinrich Nettekoven
Jean-Marc Plancher
Hans Richter
Olivier Roche
Sven Taylor
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081750A1 publication Critical patent/PE20081750A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES C(O), S(O)2; R1 ES ALQUILO INFERIOR, CICLOALQUILO HALOGENOALQUILO INFEROR, ENTRE OTROS; R2 ES H, ALQUILO INFERIOR, CICLOALQUILO, ALCANOILO INFERIOR, ENTRE OTROS; R3 ES H, HALOGENO, METILO; G ES G1, G2; R6 ES ALQUILO INFERIOR, CICLOALQUILO, CICLOALQUILO INFERIO; ENTRE OTROS; R7 ES H O R6 Y R7 JUNTOS OSN -(CH2)m- Y ESTAN UNIDOS ENTRE SI PARA FORMAR UN ANILLO JUNTO CON EL ATOMO DE CARBONO O NITROGENO AL QUE ESTAN UNIDOS; m ES 3-4; n Y p SON CADA UNO 1-2; R8 ES H, HETEROCICLILALQUILO INFERIOR; R9 Y R10 SON CADA UNO H, -N(ALQUILO INFERIOR)-, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [5-(4-ISOPROPIL-PIPERAZINA-1-CARBONIL)-1H-INDOL-2-IL]-(4-METANOSULFONIL-PIPERAZIN-1-IL)-METANONA; [1-CICLOPROPILMETIL-5-(4-ISOPROPIL-PIPERAZINA-1-CARBONIL)-1H-INDOL-2-IL]-[4-(PIPERIDINA-1-SULFONIL)PIPERAZIN-1-IL]-METANONA; ENTRE OTROS. REFERIDA TAMBIEN A COMPOSICIONES FARMACEUTICAS. DICHO COMPUESTO ES MODULADOR DEL RECEPTOR DE LA H3 UTIL EN EL TRATAMIENTO DE LA OBESIDAD
PE2008000254A 2007-02-07 2008-02-05 Derivados de 5-amido-(1h-indol-2-il)-piperazin-1-il-metanona PE20081750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101883 2007-02-07

Publications (1)

Publication Number Publication Date
PE20081750A1 true PE20081750A1 (es) 2008-12-06

Family

ID=39493651

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000254A PE20081750A1 (es) 2007-02-07 2008-02-05 Derivados de 5-amido-(1h-indol-2-il)-piperazin-1-il-metanona

Country Status (10)

Country Link
US (1) US7648979B2 (es)
EP (1) EP2118059A1 (es)
JP (1) JP2010518044A (es)
CN (1) CN101610998A (es)
AR (1) AR065181A1 (es)
CA (1) CA2676268A1 (es)
CL (1) CL2008000366A1 (es)
PE (1) PE20081750A1 (es)
TW (1) TW200843774A (es)
WO (1) WO2008095823A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
GB0813144D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
CN101747321B (zh) * 2009-12-22 2013-01-02 浙江大学 吲哚-3-苄胺衍生物及制备方法和用途
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008143A (es) * 2001-03-09 2005-08-16 Johnson & Johnson Compuestos heterociclicos.
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
DK1761519T3 (da) 2004-06-21 2008-07-21 Hoffmann La Roche Indolderivater som histaminreceptorantagonister
EP1776106B1 (en) * 2004-06-22 2013-08-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
CN101107227B (zh) 2005-01-19 2010-09-22 霍夫曼-拉罗奇有限公司 5-氨基吲哚衍生物
KR20090024115A (ko) 2006-04-12 2009-03-06 에프. 호프만-라 로슈 아게 5-아미도-2-카복스아마이드 인돌

Also Published As

Publication number Publication date
US7648979B2 (en) 2010-01-19
EP2118059A1 (en) 2009-11-18
CL2008000366A1 (es) 2008-08-08
US20080188487A1 (en) 2008-08-07
JP2010518044A (ja) 2010-05-27
TW200843774A (en) 2008-11-16
CN101610998A (zh) 2009-12-23
AR065181A1 (es) 2009-05-20
WO2008095823A1 (en) 2008-08-14
CA2676268A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
AR061486A1 (es) Derivados de 2-pirazinacarboxamida
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
AR049696A1 (es) Derivados de indol
PE20081750A1 (es) Derivados de 5-amido-(1h-indol-2-il)-piperazin-1-il-metanona
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
PE20090057A1 (es) Compuestos y composiciones como moduladores de la actividad gpr119
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
TNSN08311A1 (en) Indole sulfonamide modulators of progesterone receptors
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
PE20081504A1 (es) Compuestos de biciclocarboxiamida sustituidos
PE20100718A1 (es) Derivados triciclicos de 1, 4-dihidropiridina [b, e]-condensados como inhibidores de aurora quinasas
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20060273A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.

Legal Events

Date Code Title Description
FD Application declared void or lapsed